<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Arch Med Sci</journal-id><journal-id journal-id-type="publisher-id">AMS</journal-id><journal-title-group><journal-title>Archives of Medical Science : AMS</journal-title></journal-title-group><issn pub-type="ppub">1734-1922</issn><issn pub-type="epub">1896-9151</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28507568</article-id><article-id pub-id-type="pmc">5420627</article-id><article-id pub-id-type="publisher-id">28358</article-id><article-id pub-id-type="doi">10.5114/aoms.2016.62448</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bosone</surname><given-names>Daniele</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Alfredo</given-names></name><xref ref-type="aff" rid="aff0001">1</xref><xref ref-type="aff" rid="aff0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Ghiotto</surname><given-names>Natascia</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramusino</surname><given-names>Matteo Cotta</given-names></name><xref ref-type="aff" rid="aff0001">1</xref><xref ref-type="aff" rid="aff0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Zoppi</surname><given-names>Annalisa</given-names></name><xref ref-type="aff" rid="aff0003">3</xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Angelo</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="aff0003">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fogari</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib></contrib-group><aff id="aff0001"><label>1</label>Interinstitutional Center of Neurological Medicine, IRCCS C. Mondino National Neurological Institute, Pavia, Italy</aff><aff id="aff0002"><label>2</label>Department of Neurosciences and Behaviour, University of Pavia, Pavia, Italy</aff><aff id="aff0003"><label>3</label>Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Prof. Roberto Fogari, Department of Neurosciences and Behaviour, National Institute of Neurology IRCCS C. Mondino Foundation, University of Pavia, Via Mondino 2, 27100 Pavia, Italy. Phone: +39 0382526217. E-mail: <email xlink:href="r.fogari@unipv.it">r.fogari@unipv.it</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="ppub"><day>01</day><month>4</month><year>2017</year></pub-date><volume>13</volume><issue>3</issue><fpage>550</fpage><lpage>557</lpage><history><date date-type="received"><day>02</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Termedia &#x00026; Banach</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><sec id="s1"><title>Introduction</title><p>The aim of this study was to compare the effect of ramipril/canrenone versus ramipril/hydrochlorothiazide (HCTZ) combination on atrial fibrillation (AF) recurrence in type 2 diabetic hypertensives with and without cardiac autonomic neuropathy (CAN).</p></sec><sec id="s2"><title>Material and methods</title><p>A total of 289 hypertensive type 2 diabetic patients, 95 with CAN, in sinus rhythm but with at least two episodes of AF in the previous 6 months were randomized to ramipril 5 mg plus canrenone 50 mg (titrated to 10/100 mg) or to ramipril 5 mg plus HCTZ 12.5 mg (titrated to 10/25 mg) or to amlodipine 5 mg (titrated to 10 mg) for 1 year. Clinic blood pressure (BP) and a 24-h ECG were evaluated monthly. Patients were asked to report any episode of symptomatic AF and to perform an ECG as early as possible. Serum procollagen type I carboxy-terminal peptide (PIP) and carboxy-terminal telopeptide of collagen type I (CITP) were evaluated before and after each treatment period.</p></sec><sec id="s3"><title>Results</title><p>Blood pressure was similarly and significantly reduced by all treatments. A total of 51% of patients with amlodipine had a recurrence of AF, as did 31% of patients with ramipril/HCTZ (<italic>p</italic> &#x0003c; 0.05 vs. amlodipine) and 13% of patients with ramipril/canrenone (<italic>p</italic> &#x0003c; 0.01 vs. amlodipine and <italic>p</italic> &#x0003c; 0.05 vs. ramipril/HCTZ). A similar trend was found in diabetic patients with CAN. Both combinations reduced PIP and increased CITP, but the effects of ramipril/canrenone were significantly more marked.</p></sec><sec id="s4"><title>Conclusions</title><p>These findings suggest that in type 2 diabetic hypertensives, ramipril/canrenone treatment was more effective than ramipril/HCTZ in reducing AF recurrence. This could be related to the greater improvement in cardiac fibrosis.</p></sec></abstract><kwd-group><kwd>diabetes mellitus</kwd><kwd>atrial fibrillation</kwd><kwd>antihypertensive treatment</kwd><kwd>canrenone</kwd><kwd>cardiac autonomic neuropathy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Atrial fibrillation (AF) is frequently observed in diabetic patients [<xref rid="cit0001" ref-type="bibr">1</xref>&#x02013;<xref rid="cit0003" ref-type="bibr">3</xref>]. Subjects with diabetes frequently suffer from cardiac autonomic neuropathy (CAN) [<xref rid="cit0004" ref-type="bibr">4</xref>, <xref rid="cit0005" ref-type="bibr">5</xref>], which may contribute to creation of electrical instability leading to AF [<xref rid="cit0002" ref-type="bibr">2</xref>]. The renin-angiotensin-aldosterone system (RAAS) is well known to play a major role in the pathophysiology of AF, being involved in myocardial fibrosis, oxidative stress, inflammation and electrical abnormalities, which all contribute to the atrial remodeling underlying the occurrence of this arrhythmia [<xref rid="cit0006" ref-type="bibr">6</xref>]. As a consequence, RAAS blockade has been shown to be effective in preventing new onset as well as recurrence of AF in a variety of clinical settings [<xref rid="cit0007" ref-type="bibr">7</xref>].</p><p>Lately the role of aldosterone in AF pathophysiology has been recognized with special focus on the effects on AF-induced structural and electrical atrial remodeling [<xref rid="cit0008" ref-type="bibr">8</xref>]. Accordingly, a positive role of aldosterone and mineralocorticoid receptor (MR) antagonism in &#x0201c;upstream&#x0201d; treatment of AF has been suggested, although no definite clinical data exist in this regard [<xref rid="cit0009" ref-type="bibr">9</xref>, <xref rid="cit0010" ref-type="bibr">10</xref>]. There is evidence that MR antagonism may reduce the incidence of AF in patients with heart failure [<xref rid="cit0010" ref-type="bibr">10</xref>, <xref rid="cit0011" ref-type="bibr">11</xref>], whereas some studies suggested that it may be useful to add an aldosterone/MR antagonist to ACE-I or ARBs in patients with AF [<xref rid="cit0012" ref-type="bibr">12</xref>].</p><p>Given that treatment of hypertensive patients with diabetes almost always requires combination of two or more drugs [<xref rid="cit0013" ref-type="bibr">13</xref>], the aim of the present study was to evaluate the effect of the ACE-I ramipril plus the aldosterone antagonist canrenone as compared to ramipril/hydrochlorothiazide (HCTZ) combination in preventing the recurrence of AF in hypertensive patients with diabetes mellitus and a history of a recent AF episode. The effects on P-wave dispersion (PWD), assessed as a marker of inhomogeneous atrial propagation of sinus impulses [<xref rid="cit0014" ref-type="bibr">14</xref>], were also evaluated, as were the effects on serum procollagen type 1 carboxy-terminal peptide (PIP) levels, used as a marker of extracellular collagen type 1 synthesis and myocardial fibrosis [<xref rid="cit0015" ref-type="bibr">15</xref>] and on carboxy-terminal telopeptide of collagen type 1 (CITP), used as marker of extracellular collagen type 1 degradation [<xref rid="cit0012" ref-type="bibr">12</xref>, <xref rid="cit0013" ref-type="bibr">13</xref>]. Due to the role of CAN in AF pathophysiology, the effects of study medications were evaluated in patients with and without CAN.</p></sec><sec sec-type="material|methods" id="sec2"><title>Material and methods</title><p>This was a prospective, randomized, double-blind, parallel-arm trial. The study population was selected according to the following inclusion criteria: outpatients of either sex with essential hypertension (systolic blood pressure (SBP) &#x02265; 140 and &#x0003c; 160 mm Hg and/or diastolic blood pressure (DBP) &#x02265; 90 and &#x0003c; 100 mm Hg at the end of a 2-week wash-out period) and well-controlled diabetes mellitus (glycated haemoglobin (HbA<sub>1c</sub>) &#x0003c; 7%) in sinus rhythm but with at least 2 ECG-documented episodes of symptomatic AF in the previous 6 months. Previous AF episodes could be self-terminating or terminated after pharmacological and/or electrical cardioversion. Exclusion criteria were: secondary hypertension, cardioversion within the last 8 weeks, in current treatment with angiotensin converting enzyme-inhibitors (ACE-I), angiotensin II receptor blockers (ARBs) or &#x003b2;-blockers, antiarrhythmic agents, myocardial infarction or stroke in the previous 6 months, congestive heart failure, left atrium size &#x0003e; 45 mm, need to continue the use of digitalis, cardiac surgery during the preceding 6 months, significant thyroid, renal or hepatic disease, pregnancy, and known contraindications to the study medications. The study protocol was approved by the local Ethical Committee, and informed consent was obtained from each participant.</p><p>The patients were evaluated for CAN using 4 different clinical tests: 1) heart rate variability: the standard deviation of 150 consecutive R-R intervals recorded while the subjects lay quietly breathing when &#x02264; 2 mms was considered abnormal; 2) resting heart rate (HR): a resting HR of more than 100 beats per minute was considered abnormal; 3) orthostatic hypotension: BP was first measured in a supine position and then after 2 min of standing; a fall in SBP of &#x0003e; 20 mm Hg and/or in DBP &#x0003e; 10 mm Hg was considered abnormal; 4) ECG recording &#x02013; QTc interval &#x0003e; 440 ms was considered abnormal. If two or more of the above tests were abnormal, the patient was diagnosed as positive for CAN. We choose to use the above described tests for CAN detection instead of the widely used Ewing tests [<xref rid="cit0016" ref-type="bibr">16</xref>] because two of the latter, i.e. the Valsalva maneuver and handgrip test, require full cooperation of the patient, which would have been difficult to obtain in elderly patients such as those enrolled in the present study.</p><p>After an initial 2-week antihypertensive wash-out period on placebo, patients were randomly assigned to receive ramipril 5 mg plus 50 mg of canrenone or ramipril 5 mg plus 12.5 mg of HCTZ or 5 mg of amlodipine once daily (od). In non-responder patients (BP &#x0003e; 135/85 mm Hg), the study drugs were titrated after 4 weeks (ramipril/canrenone 5/100 mg, ramipril HCTZ 5/25 mg and amlodipine 7.5 mg) and 8 weeks (ramipril/canrenone 10/100 mg, ramipril HCTZ 10/25 mm Hg and amlodipine 10 mg) to achieve a target BP of less than 135/85 mm Hg (<xref ref-type="fig" rid="f0001">Figure 1</xref>). Those patients who did not achieve the target BP after 12 weeks were excluded. Patients were checked every 4 weeks for 1 year. Clinical examination included BP evaluation, a resting ECG and a 24-h ECG registration (using a Syneflah Holter recorder, Ela Medical, Paris, France) [<xref rid="cit0017" ref-type="bibr">17</xref>]. Patients were also asked to report any episode of palpitations, to take their pulse and, in presence of arrhythmia, to perform an ECG as early as possible. Only AF episodes confirmed with an ECG were considered as recurrences.</p><fig id="f0001" position="float"><label>Figure 1</label><caption><p>Study design</p></caption><graphic xlink:href="AMS-13-28358-g001"/></fig><p>At the end of the placebo period and of each treatment period, PWD was evaluated and serum PIP and CITP levels were determined.</p><p>P-wave analysis measurements were calculated in 12-lead surface ECG recordings obtained at a paper speed of 50 mm/s and were transferred into a computer and opened with a high-performance graphic program. Measurements of P duration were performed by two cardiologists blinded to the patients&#x02019; clinical data. Four cycles were measured for each lead. The difference between maximum and minimum P duration was defined as PWD [<xref rid="cit0018" ref-type="bibr">18</xref>]. Blood samples for PIP and CITP evaluation were taken in the morning after an overnight fast. Serum PIP was determined by a rapid equilibrium radioimmunoassay according to the method of Meikko <italic>et al.</italic> [<xref rid="cit0019" ref-type="bibr">19</xref>] using commercial antisera specifically directed against the terminal carboxy terminal peptide. Serum CITP was also determined by a specific radioimmunoassay using specific antisera (Orion Diagnostica, Espoo, Finland), according to the method of Risteli <italic>et al.</italic> [<xref rid="cit0016" ref-type="bibr">16</xref>].</p><p>The primary end-point of the study was to assess the efficacy of ramipril/canrenone combination as compared to ramipril/HCTZ combination and amlodipine with regard to the cumulative number of patients relapsing into documented atrial fibrillation. Secondary end points were time to a first ECG-confirmed recurrence of AF, the changes in PWD and the changes in PIP and CITP serum levels.</p><sec id="sec2.1"><title>Statistical analysis</title><p>The sample size calculations are based on an estimated efficacy at 1 year of 75% for ramipril/canrenone, 80% for ramipril/HCTZ and 60% for amlodipine. With a level of 0.05 and a test power of 0.80, the resulting sample size was 87 patients for each treatment group. Data are expressed as means &#x000b1; SD for continuous variables, and frequencies were measured for categorical variables. Baseline characteristics were examined for statistical significance for continuous variables using Student&#x02019;s <italic>t</italic>-test. The Fisher exact test was used for categorical variables. The end points were analyzed on an intention-to-treat basis. The number of days to AF recurrence (median and range) was compared among the treatment groups by the non-parametric Wilcoxon test.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><p>A total of 342 consecutive hypertensive patients with type 2 diabetes were referred to our hypertension center with a history of paroxysmal AF. Of them 289 were finally randomized to participate in this study (<xref ref-type="fig" rid="f0002">Figure 2</xref>). Ninety-five (32.8%) patients were found to have CAN. Forty-two patients were excluded from this protocol according to the inclusion/exclusion criteria. Twelve patients refused to participate. The baseline demographic and clinical characteristics of each treatment group are shown in <xref ref-type="table" rid="t0001">Table I</xref>. Patients in the 3 groups were well matched and similar with regard to all pre-treatment characteristics.</p><table-wrap id="t0001" position="float"><label>Table I</label><caption><p>Main demographic and clinic characteristics of patients in the three treatment groups</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Amlodipine (<italic>n</italic> = 94)</th><th align="center" rowspan="1" colspan="1">Ramipril/HCTZ (<italic>n</italic> = 97)</th><th align="center" rowspan="1" colspan="1">Ramipril/canrenone (<italic>n</italic> = 98)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age [years]</td><td align="center" rowspan="1" colspan="1">68 &#x000b1;7.5</td><td align="center" rowspan="1" colspan="1">67 &#x000b1;7.1</td><td align="center" rowspan="1" colspan="1">68 &#x000b1;8.2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (M/F)</td><td align="center" rowspan="1" colspan="1">45/49</td><td align="center" rowspan="1" colspan="1">46/51</td><td align="center" rowspan="1" colspan="1">48/50</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight [kg]</td><td align="center" rowspan="1" colspan="1">75.4 &#x000b1;10.1</td><td align="center" rowspan="1" colspan="1">75.7 &#x000b1;10.5</td><td align="center" rowspan="1" colspan="1">76.2 &#x000b1;10.6</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP [mm Hg]</td><td align="center" rowspan="1" colspan="1">148.8 &#x000b1;7.3</td><td align="center" rowspan="1" colspan="1">148.2 &#x000b1;7.5</td><td align="center" rowspan="1" colspan="1">149.1 &#x000b1;7.8</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP [mm Hg]</td><td align="center" rowspan="1" colspan="1">92.3 &#x000b1;3.7</td><td align="center" rowspan="1" colspan="1">92.7 &#x000b1;3.5</td><td align="center" rowspan="1" colspan="1">93.1 &#x000b1;3.9</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate [bpm]</td><td align="center" rowspan="1" colspan="1">76.1 &#x000b1;9.9</td><td align="center" rowspan="1" colspan="1">75.9 &#x000b1;10.8</td><td align="center" rowspan="1" colspan="1">75.5 &#x000b1;11.2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG [mg/dl]</td><td align="center" rowspan="1" colspan="1">126.1 &#x000b1;19.3</td><td align="center" rowspan="1" colspan="1">123.4 &#x000b1;20.2</td><td align="center" rowspan="1" colspan="1">125.3 &#x000b1;18.6</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)</td><td align="center" rowspan="1" colspan="1">6.8 &#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">6.6 &#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">6.7 &#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum potassium [mEq/l]</td><td align="center" rowspan="1" colspan="1">4.49 &#x000b1;0.39</td><td align="center" rowspan="1" colspan="1">4.43 &#x000b1;0.36</td><td align="center" rowspan="1" colspan="1">4.52 &#x000b1;0.35</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR [ml/min/1.73 m<sup>2</sup>]</td><td align="center" rowspan="1" colspan="1">86.6 &#x000b1;5.9</td><td align="center" rowspan="1" colspan="1">88.1 &#x000b1;6.2</td><td align="center" rowspan="1" colspan="1">83.7 &#x000b1;5.7</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Echocardiogram:</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LV end-diastolic dimension [mm]</td><td align="center" rowspan="1" colspan="1">50.8 &#x000b1;0.7</td><td align="center" rowspan="1" colspan="1">51.5 &#x000b1;0.6</td><td align="center" rowspan="1" colspan="1">50.4 &#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">61.2 &#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">62.1 &#x000b1;8.3</td><td align="center" rowspan="1" colspan="1">60.7 &#x000b1;8.9</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LA inferosuperior dimension [mm]</td><td align="center" rowspan="1" colspan="1">42.8 &#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">42.6 &#x000b1;2.1</td><td align="center" rowspan="1" colspan="1">42.9 &#x000b1;2.2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Septal thickness [mm]</td><td align="center" rowspan="1" colspan="1">11.3 &#x000b1;0.29</td><td align="center" rowspan="1" colspan="1">11.1 &#x000b1;0.33</td><td align="center" rowspan="1" colspan="1">11.4 &#x000b1;0.27</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;AF episodes (number)</td><td align="center" rowspan="1" colspan="1">2.6 &#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">2.8 &#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">2.7 &#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; SD. SBP &#x02013; systolic blood pressure, DBP &#x02013; diastolic blood pressure, FPG &#x02013; fasting plasma glucose, HbA<sub>1c</sub> &#x02013; glycated hemoglobin, eGFR &#x02013; estimated glomerular filtration rate, LV &#x02013; left ventricular, LA &#x02013; left atrial, AF &#x02013; atrial fibrillation.</p></fn></table-wrap-foot></table-wrap><fig id="f0002" position="float"><label>Figure 2</label><caption><p>Flow diagram of the study</p></caption><graphic xlink:href="AMS-13-28358-g002"/></fig><p>A total of 98 patients were allocated for treatment with ramipril/canrenone combination, 97 for treatment with ramipril/HCTZ combination and 94 for treatment with amlodipine. There were substantial reductions in SBP and DBP values in all treatment groups. At the end of follow-up SBP was reduced by 18.9 mm Hg (<italic>p</italic> &#x0003c; 0.001) with ramipril/canrenone, by 19.3 mm Hg (<italic>p</italic> &#x0003c; 0.001) with ramipril/HCTZ and by 17.2 mm Hg (<italic>p</italic> &#x0003c; 0.001) with amlodipine, with no significant difference among treatments. Corresponding changes for DBP were 14.5, 14.9 and 13.6 mm Hg (<italic>p</italic> &#x0003c; 0.001 vs. baseline), respectively, again without any significant difference among treatments. Heart rate did not show any significant change from baseline.</p><p>Results regarding AF recurrence are shown in <xref ref-type="table" rid="t0002">Tables II</xref> and <xref ref-type="table" rid="t0003">III</xref>. At the 4-month follow-up visit (end of titration period), 37 patients had a recurrence of AF by intention-to-treat analysis; the occurrence rate was lower in the ramipril/canrenone group (9 patients) than in the ramipril/HCTZ group (11 patients) and the amlodipine group (17 patients), the difference of ramipril/canrenone vs amlodipine being statistically significant (<italic>p</italic> &#x0003c; 0.05).</p><table-wrap id="t0002" position="float"><label>Table II</label><caption><p>Main results of the study according to an intention-to-treat analysis</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Amlodipine</th><th align="center" rowspan="1" colspan="1">Ramipril/HCTZ</th><th align="center" rowspan="1" colspan="1">Ramipril/canrenone</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients randomized</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">98</td></tr><tr><td align="left" rowspan="1" colspan="1">AF recurrence at 4 months after randomization (end of titration)</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">9<sup><xref ref-type="table-fn" rid="tf2-1">a</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">AF recurrence at 1 year after randomization (end of follow-up)</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">30<sup><xref ref-type="table-fn" rid="tf2-1">a</xref></sup></td><td align="center" rowspan="1" colspan="1">13<sup><xref ref-type="table-fn" rid="tf2-2">b</xref>,<xref ref-type="table-fn" rid="tf2-3">c</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Days to recurrence, median &#x000b1; SD (range)</td><td align="center" rowspan="1" colspan="1">69 &#x000b1;31 (28&#x02013;329)</td><td align="center" rowspan="1" colspan="1">139 &#x000b1;73<sup><xref ref-type="table-fn" rid="tf2-1">a</xref></sup> (39&#x02013;336)</td><td align="center" rowspan="1" colspan="1">175 &#x000b1;91<sup><xref ref-type="table-fn" rid="tf2-1">a</xref></sup> (48&#x02013;349)</td></tr></tbody></table><table-wrap-foot><fn id="tf2-1"><label>a</label><p>p &#x0003c; 0.05 vs. amlodipine,</p></fn><fn id="tf2-2"><label>b</label><p>p &#x0003c; 0.01 vs. amlodipine,</p></fn><fn id="tf2-3"><label>c</label><p>p &#x0003c; 0.05 vs. ramipril/HCTZ, AF &#x02013; atrial fibrillation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0003" position="float"><label>Table III</label><caption><p>Main results according to an intention-to-treat analysis in the subgroup of patients with CAN at baseline</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Amlodipine</th><th align="center" rowspan="1" colspan="1">Ramipril/HCTZ</th><th align="center" rowspan="1" colspan="1">Ramipril/canrenone</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">AF recurrence at 4 months after randomization (end of titration)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">AF recurrence at 1 year after randomization (end of follow-up)</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">5<xref ref-type="table-fn" rid="tf3-1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Days to recurrence, median &#x000b1; SD (range)</td><td align="center" rowspan="1" colspan="1">58 &#x000b1;25 (21&#x02013;211)</td><td align="center" rowspan="1" colspan="1">91 &#x000b1;49 (32&#x02013;229)</td><td align="center" rowspan="1" colspan="1">106 &#x000b1;69 (39&#x02013;244)</td></tr></tbody></table><table-wrap-foot><fn id="tf3-1"><label>*</label><p>p &#x0003c; 0.05 vs. amlodipine. AF &#x02013; atrial fibrillation.</p></fn></table-wrap-foot></table-wrap><p>At the end of the follow-up, 48 (51%) patients undergoing treatment with amlodipine had a recurrence of AF, as did 30 patients (31%) undergoing treatment with ramipril plus HCTZ (<italic>p</italic> &#x0003c; 0.05 vs. amlodipine) and 13 (13%) patients undergoing treatment with ramipril plus canrenone (<italic>p</italic> &#x0003c; 0.01 vs. amlodipine and <italic>p</italic> &#x0003c; 0.05 vs. ramipril/HCTZ). The time to a first ECG-confirmed recurrence of AF was of 69 &#x000b1;31 days (median &#x000b1; SD) in the amlodipine group, of 139 &#x000b1;73 days in the ramipril/HCTZ group (<italic>p</italic> &#x0003c; 0.05 vs. amlodipine) and of 175 &#x000b1;91 days in the ramipril/canrenone group (<italic>p</italic> &#x0003c; 0.01 vs. amlodipine and <italic>p</italic> &#x0003c; 0.05 vs. ramipril/HCTZ).</p><p><xref ref-type="table" rid="t0003">Table III</xref> shows the main results according to an intention-to treat analysis in the subgroup of patients with CAN at baseline. At the end of follow-up the number of patients who had a recurrence of AF was lower in the ramipril/canrenone group (5) than in the ramipril/HCTZ group (12) and the amlodipine group (17). Similarly, the number of days to AF recurrence was higher in the ramipril canrenone group (116 &#x000b1;69) than in the ramipril/HCTZ group (91 &#x000b1;49) and the amlodipine group (58 &#x000b1;25), but the differences among treatments were not statistically significant.</p><p>The percentage of patients with CAN who had an AF recurrence was not different from that of the total population in all the 3 treatment groups: 54.8% vs. 51.1% with amlodipine, 35.2% vs. 31.% with ramipril/HCTZ and 16.6 vs. 13.3% with ramipril/canrenone.</p><p>The PWD values did not show any significant change in the amlodipine treated patients, whereas a significant reduction was observed in both the ramipril/HCTZ (<italic>p</italic> &#x0003c; 0.05 vs. baseline) and the ramipril/canrenone group (<italic>p</italic> &#x0003c; 0.01 vs. baseline). Such a reduction was significantly greater in the ramipril/canrenone than in the ramipril/HCTZ treated patients (<italic>p</italic> &#x0003c; 0.01) (<xref ref-type="table" rid="t0004">Table IV</xref>).</p><table-wrap id="t0004" position="float"><label>Table IV</label><caption><p>P-wave dispersion and serum PIP and CITP values before and after treatment in patients who completed the study without any AF recurrence</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Amlodipine (<italic>n</italic> = 24)</th><th align="center" rowspan="1" colspan="1">Ramipril/HCTZ (<italic>n</italic> = 49)</th><th align="center" rowspan="1" colspan="1">Ramipril/canrenone (<italic>n</italic> = 71)</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">PWD [ms]:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="center" rowspan="1" colspan="1">39.3 &#x000b1;10.8</td><td align="center" rowspan="1" colspan="1">40.2 &#x000b1;8.7</td><td align="center" rowspan="1" colspan="1">39.8 &#x000b1;9.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Treatment</td><td align="center" rowspan="1" colspan="1">40.1 &#x000b1;11.9</td><td align="center" rowspan="1" colspan="1">34.5 &#x000b1;9.1<sup><xref ref-type="table-fn" rid="tf4-1">a</xref></sup></td><td align="center" rowspan="1" colspan="1">27.1 &#x000b1;7.9<sup><xref ref-type="table-fn" rid="tf4-2">b</xref>,<xref ref-type="table-fn" rid="tf4-4">d</xref>,<xref ref-type="table-fn" rid="tf4-5">e</xref></sup></td></tr><tr><td colspan="4" rowspan="1">Serum PIP [&#x000b5;g/l]:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="center" rowspan="1" colspan="1">148.5 &#x000b1;35.2</td><td align="center" rowspan="1" colspan="1">147.2 &#x000b1;34.6</td><td align="center" rowspan="1" colspan="1">149.8 &#x000b1;36.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Treatment</td><td align="center" rowspan="1" colspan="1">138.1 &#x000b1;32.7</td><td align="center" rowspan="1" colspan="1">101.8 &#x000b1;24.7<sup><xref ref-type="table-fn" rid="tf4-2">b</xref>,<xref ref-type="table-fn" rid="tf4-3">c</xref></sup></td><td align="center" rowspan="1" colspan="1">84.2 &#x000b1;18.3<sup><xref ref-type="table-fn" rid="tf4-2">b</xref>,<xref ref-type="table-fn" rid="tf4-4">d</xref>,<xref ref-type="table-fn" rid="tf4-5">e</xref></sup></td></tr><tr><td colspan="4" rowspan="1">Serum CITP [&#x000b5;g/l]:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="center" rowspan="1" colspan="1">2.44 &#x000b1;1.23</td><td align="center" rowspan="1" colspan="1">2.48 &#x000b1;1.26</td><td align="center" rowspan="1" colspan="1">2.49 &#x000b1;1.25</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Treatment</td><td align="center" rowspan="1" colspan="1">2.49 &#x000b1;1.28</td><td align="center" rowspan="1" colspan="1">2.68 &#x000b1;1.28<sup><xref ref-type="table-fn" rid="tf4-1">a</xref></sup></td><td align="center" rowspan="1" colspan="1">3.11 &#x000b1;1.29<sup><xref ref-type="table-fn" rid="tf4-2">b</xref>,<xref ref-type="table-fn" rid="tf4-4">d</xref>,<xref ref-type="table-fn" rid="tf4-5">e</xref></sup></td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; SD.</p></fn><fn id="tf4-1"><label>a</label><p>p &#x0003c; 0.05 vs. placebo,</p></fn><fn id="tf4-2"><label>b</label><p>p &#x0003c; 0.01 vs. placebo,</p></fn><fn id="tf4-3"><label>c</label><p>p &#x0003c; 0.05 vs. amlodipine,</p></fn><fn id="tf4-4"><label>d</label><p>p &#x0003c; 0.01 vs. amlodipine,</p></fn><fn id="tf4-5"><label>e</label><p>p &#x0003c; 0.05 vs. ramipril/HCTZ. PWD &#x02013; P-wave dispersion, PIP &#x02013; propeptide of procollagen type I, CITP &#x02013; carboxy-terminal telopeptide of collagen type I.</p></fn></table-wrap-foot></table-wrap><p>Serum PIP levels were not affected by amlodipine treatment, whereas they were reduced by both ramipril plus HCTZ (<italic>p</italic> &#x0003c; 0.01 vs. baseline and <italic>p</italic> &#x0003c; 0.05 vs. amlodipine) and ramipril plus canrenone (<italic>p</italic> &#x0003c; 0.01 vs. baseline and vs. amlodipine). The reduction was significantly greater in the ramipril/canrenone than in the ramipril/HCTZ group (<italic>p</italic> &#x0003c; 0.01) (<xref ref-type="table" rid="t0004">Table IV</xref>).</p><p>Serum CITP levels were not affected by amlodipine treatment, whereas they were increased by both ramipril plus HCTZ (<italic>p</italic> &#x0003c; 0.05 vs. baseline) and ramipril plus canrenone (<italic>p</italic> &#x0003c; 0.01 vs. baseline and vs amlodipine). Again the increase was significantly greater in the ramipril plus canrenone than in the ramipril/HCTZ treated patients (<italic>p</italic> &#x0003c; 0.05).</p><p>No significant change in fasting plasma glucose values was observed in the 3 treatment groups (<xref ref-type="table" rid="t0005">Table V</xref>). Similarly, no significant change was observed in serum potassium levels or glomerular filtration rate (GFR) (<xref ref-type="table" rid="t0005">Table V</xref>).</p><table-wrap id="t0005" position="float"><label>Table V</label><caption><p>Adverse events and biochemical parameters at the end of the follow-up</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Amlodipine (<italic>n</italic> = 94)</th><th align="center" rowspan="1" colspan="1">Ramipril/HCTZ (<italic>n</italic> = 97)</th><th align="center" rowspan="1" colspan="1">Ramipril/canrenone (<italic>n</italic> = 98)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Adverse events</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG [mg/dl]</td><td align="center" rowspan="1" colspan="1">125.2 &#x000b1;17.3</td><td align="center" rowspan="1" colspan="1">126.6 &#x000b1;19.4</td><td align="center" rowspan="1" colspan="1">124.9 &#x000b1;18.8</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum potassium [mEq/l]</td><td align="center" rowspan="1" colspan="1">4.51 &#x000b1;0.41</td><td align="center" rowspan="1" colspan="1">4.29 &#x000b1;0.34</td><td align="center" rowspan="1" colspan="1">4.67 &#x000b1;0.39</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR [ml/min/1.73 m<sup>2</sup>]</td><td align="center" rowspan="1" colspan="1">85.8 &#x000b1;5.7</td><td align="center" rowspan="1" colspan="1">87.4 &#x000b1;6.3</td><td align="center" rowspan="1" colspan="1">84.5 &#x000b1;5.4</td><td align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; SD. FPG &#x02013; fasting plasma glucose, eGFR &#x02013; estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap><p>Adverse events requiring the discontinuation of treatment occurred in 3 patients in the ramipril/canrenone group, 6 patients in the ramipril/HCTZ group and in 6 patients in the amlodipine group, with no significant difference among the 3 treatment groups.</p></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>The results of this study showed that in hypertensive patients with type 2 diabetes and a history of AF episodes antihypertensive treatment with both ramipril/canrenone and ramipril/HCTZ combination was more effective than amlodipine monotherapy in reducing new episodes of AF, but the preventive effect of ramipril plus canrenone on AF relapse was significantly greater than that of ramipril plus HCTZ despite a similar BP reduction. These results were already evident after 3 months of therapy and persisted after 1 year, when the difference between the two combinations was more marked.</p><p>These findings on one hand confirm that ACE inhibition per se may be effective in preventing AF recurrence, which is in agreement with previous observations [<xref rid="cit0020" ref-type="bibr">20</xref>&#x02013;<xref rid="cit0022" ref-type="bibr">22</xref>]. Such a preventive effect has been related to several mechanisms, including inhibition of angiotensin II-induced myocardial fibrosis, interference with ion channel function, in particular K<sup>+</sup> channel subunits and Ca<sup>++</sup> ion currents, modulation of refractoriness, reduced atrial stretch, improved left ventricular hemodynamics and modulation of sympathetic nerve activity [<xref rid="cit0023" ref-type="bibr">23</xref>, <xref rid="cit0024" ref-type="bibr">24</xref>]. On the other hand, the findings of this study indicate that adding an antialdosteronic drug such as canrenone to an ACE-I may provide a greater AF-preventing effect, possibly related to the positive impact of aldosterone inhibition on the atrial electrical and structural remodeling documented by the effects on PWD as well as on PIP and CITP levels.</p><p>Inhomogeneous atrial propagation of sinus impulses, marked by PWD, has been demonstrated to be an independent predictor for AF [<xref rid="cit0014" ref-type="bibr">14</xref>, <xref rid="cit0025" ref-type="bibr">25</xref>]. In the present study, both combinations significantly reduced PWD, but the reducing effect of the latter was more marked. Aldosterone, whose levels are elevated in patients with AF [<xref rid="cit0026" ref-type="bibr">26</xref>], has been demonstrated to affect atrial electrophysiology via modulation of both K<sup>+</sup> and Ca<sup>++</sup> channels [<xref rid="cit0027" ref-type="bibr">27</xref>]. It increases L-type calcium currents and prolongs action potential duration, which may result in early afterdepolarizations [<xref rid="cit0028" ref-type="bibr">28</xref>]. It also alters repolarizing potassium currents [<xref rid="cit0027" ref-type="bibr">27</xref>]. Additionally, aldosterone enhances potassium and magnesium excretion, decreases myocardial reuptake of catecholamines, attenuates baroreceptor activity, increases baroreceptor sensitivity to catecholamines and reduces sinus rhythm variability, mechanisms that all contribute to the arrhythmogenic potential of aldosterone. Therefore inhibition of aldosterone actions by canrenone might result in an AF-preventing effect at least in part through amelioration of atrial electrical remodeling.</p><p>Fibrosis in atrial muscles is another critical factor responsible for AF, mainly through decrease in the atrial conduction velocity and heterogeneity of the conduction tissue [<xref rid="cit0029" ref-type="bibr">29</xref>, <xref rid="cit0030" ref-type="bibr">30</xref>]. Increased interstitial fibrosis can physically separate myocytes, decreasing myocyte electrical coupling and creating a barrier to impulse propagation. Since the use of cardiac biopsies for documenting and measuring myocardial fibrosis is an invasive methodology not useful for wide-scale application, serological markers of collagen turnover have been introduced for non-invasive monitoring of myocardial fibrosis in clinical practice. In particular, serum concentrations of PIP and CITP may be useful for assessing the synthesis and degradation, respectively, of collagen type I fibers and provide indirect information on both the extent of myocardial fibrosis and the ability of antihypertensive agents to reduce myocardial fibrosis [<xref rid="cit0015" ref-type="bibr">15</xref>, <xref rid="cit0016" ref-type="bibr">16</xref>]. In this study, both ramipril plus HCTZ and ramipril plus canrenone significantly decreased the serum concentration of PIP and increased CITP levels, thus confirming the ability of ACE-I inhibition to reduce the synthesis and to stimulate the degradation of collagen type I fibers with consequent reduction of myocardial fibrosis [<xref rid="cit0031" ref-type="bibr">31</xref>]. These effects, however, were significantly more marked in the ramipril/canrenone treated patients, which again indicates the relevant role of aldosterone inhibition. Several studies have shown that aldosterone promotes fibrotic atrial remodeling [<xref rid="cit0032" ref-type="bibr">32</xref>, <xref rid="cit0033" ref-type="bibr">33</xref>]. It stimulates collagen I and III synthesis and fibroblasts by activating mineralocorticoid receptors, which promote gene transcription of fibrotic and hypertrophic proteins [<xref rid="cit0008" ref-type="bibr">8</xref>]. By blocking aldosterone at its receptor, canrenone would mitigate these effects, thereby reducing myocardial fibrosis, which in turn may result in prevention of AF recurrence.</p><p>Since an increase in aldosterone levels may occur during treatment with ACE-I due to the well-known phenomenon of aldosterone escape, caused by non-ACE-dependent Ang II forming activity mediated by chymase [<xref rid="cit0034" ref-type="bibr">34</xref>, <xref rid="cit0035" ref-type="bibr">35</xref>], add-on therapy with an aldosterone antagonist such as canrenone may be more effective in reducing AF recurrence than HCTZ addition, which is devoid of anti-aldosteronic action. As a corollary of this observation, we can hypothesize that the better AF preventive effect found in various studies with ARBs [<xref rid="cit0021" ref-type="bibr">21</xref>, <xref rid="cit0022" ref-type="bibr">22</xref>, <xref rid="cit0036" ref-type="bibr">36</xref>, <xref rid="cit0037" ref-type="bibr">37</xref>] might be related to the more complete blockade of the unfavorable actions of Ang II, including aldosterone production. Indeed, ARBs are effective on both ACE and non-ACE dependent Ang II/aldosterone formation.</p><p>Although the decrease in BP could be an important part of the mechanism of benefit observed with both ramipril/canrenone and ramipril/HCTZ combination, our study revealed no statistical difference in BP. This suggests that the greater preventive effect of ramipril plus canrenone was independent from its BP-lowering effect.</p><p>Similarly, since glycemic control was stable throughout the study period in all treatment groups, the observed difference in AF recurrence did not seem to be related to the difference in glycemic status.</p><p>In the subgroup of patients with CAN, no significant difference was observed with respect to the total population with any treatment. Reasons for these inconsistent findings are unclear, but we hypothesize that a greater sample size could perhaps have resulted in different data.</p><p>During the entire study period, the enrolled patients were given only the drugs included in the study protocol. This represents an advantage and a limitation at the same time. The advantage was the possibility of detecting exclusively the effects of the study medications. The limitation was that it was not possible to ascertain whether the observed effects would be the same or less evident in case of concomitant treatment with first-line drugs for AF such as &#x003b2;-blockers.</p><p>In conclusion, this study showed that antihypertensive treatment with both ramipril/canrenone and ramipril/HCTZ combination was more effective than amlodipine monotherapy in preventing AF relapse in diabetic patients with a history of AF episodes, but the effect of ramipril/canrenone was greater than that of ramipril/HCTZ. The advantage of ramipril/canrenone in preventing new episodes of AF might be related to the canrenone-mediated greater lowering effect on PWD and PIP levels and greater increasing effect on CITP levels. This in turn might reflect a more positive impact of this combination of an ACE-I with an antialdosteronic drug on atrial electrical and structural remodeling due to a more complete inhibition of the RAAS.</p></sec></body><back><sec sec-type="COI-statement"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohaved</surname><given-names>MR</given-names></name><name><surname>Hashenzadeh</surname><given-names>M</given-names></name><name><surname>Jamal</surname><given-names>MM</given-names></name></person-group><article-title>Diabetes mellitus is strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular diseases</article-title><source>Int J Cardiol</source><year>2005</year><volume>105</volume><fpage>315</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16274775</pub-id></element-citation></ref><ref id="cit0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanorskii</surname><given-names>SG</given-names></name><name><surname>Kanorskaia</surname><given-names>IuS</given-names></name></person-group><article-title>Atrial fibrillation in patients with type 2 diabetes mellitus: specific features of development and antirecurrence therapy</article-title><source>Kardiologiia</source><year>2010</year><volume>50</volume><fpage>31</fpage><lpage>7</lpage></element-citation></ref><ref id="cit0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bissinger</surname><given-names>A</given-names></name><name><surname>Ruxer</surname><given-names>J</given-names></name><name><surname>Ahmed</surname><given-names>RB</given-names></name><name><surname>Lubinski</surname><given-names>A</given-names></name></person-group><article-title>Heart rate turbulence in patients with poorly controlled diabetes mellitus type 2</article-title><source>Arch Med Sci</source><year>2014</year><volume>10</volume><fpage>1073</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25624841</pub-id></element-citation></ref><ref id="cit0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arif</surname><given-names>ZA</given-names></name><name><surname>Shaikh</surname><given-names>IA</given-names></name><name><surname>Masood</surname><given-names>N</given-names></name></person-group><article-title>Cardiovascular autonomic neuropathy (CAN) in patients of type 2 diabetes mellitus: a tertiary care hospital based study</article-title><source>Indian Heart J</source><year>2014</year><volume>66</volume><fpage>751</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">25634425</pub-id></element-citation></ref><ref id="cit0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasznicki</surname><given-names>J</given-names></name><name><surname>Drzewoski</surname><given-names>J</given-names></name></person-group><article-title>Heart failure in the diabetic population &#x02013; pathophysiology, diagnosis and management</article-title><source>Arch Med Sci</source><year>2014</year><volume>10</volume><fpage>546</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">25097587</pub-id></element-citation></ref><ref id="cit0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serra</surname><given-names>JL</given-names></name><name><surname>Bendersky</surname><given-names>M</given-names></name></person-group><article-title>Atrial fibrillation and the renin-angiotensin system</article-title><source>Ther Adv Cardiovasc Dis</source><year>2008</year><volume>2</volume><fpage>215</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19124423</pub-id></element-citation></ref><ref id="cit0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khatib</surname><given-names>R</given-names></name><name><surname>Joseph</surname><given-names>P</given-names></name><name><surname>Briel</surname><given-names>M</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Healey</surname><given-names>J</given-names></name></person-group><article-title>Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials</article-title><source>Int J Cardiol</source><year>2013</year><volume>165</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">22421406</pub-id></element-citation></ref><ref id="cit0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayyas</surname><given-names>F</given-names></name><name><surname>Alzoubi</surname><given-names>KH</given-names></name><name><surname>Van Wagoner</surname><given-names>DR</given-names></name></person-group><article-title>Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling</article-title><source>Int J Cardiol</source><year>2013</year><volume>168</volume><fpage>5135</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">23993726</pub-id></element-citation></ref><ref id="cit0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Meara</surname><given-names>E</given-names></name><name><surname>Khairy</surname><given-names>P</given-names></name><name><surname>Chabot Blanchet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the atrial fibrillation and congestive heart failure</article-title><source>Circ Heart Fail</source><year>2012</year><volume>5</volume><fpage>586</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">22798522</pub-id></element-citation></ref><ref id="cit0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mc Cullough</surname><given-names>PA</given-names></name><name><surname>Cowan</surname><given-names>S</given-names></name></person-group><article-title>Mineralcorticoid receptor antagonists and mortality in heart failure with concurrent atrial fibrillation</article-title><source>Circ Heart Fail</source><year>2012</year><volume>5</volume><fpage>550</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">22991404</pub-id></element-citation></ref><ref id="cit0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swedberg</surname><given-names>K</given-names></name><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Eplerenone and atrial fibrillation in mild systolic heart failure</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>59</volume><fpage>1598</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">22538330</pub-id></element-citation></ref><ref id="cit0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dabrowski</surname><given-names>R</given-names></name><name><surname>Borowiec</surname><given-names>A</given-names></name><name><surname>Smolis-Bak</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effect of combined spironolactone-beta-blocker enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study)</article-title><source>Am J Cardiol</source><year>2010</year><volume>106</volume><fpage>1609</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">21094362</pub-id></element-citation></ref><ref id="cit0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronow</surname><given-names>WS</given-names></name></person-group><article-title>Commentary on recent guidelines for treating hypertension</article-title><source>Arch Med Sci</source><year>2014</year><volume>10</volume><fpage>1069</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">25624840</pub-id></element-citation></ref><ref id="cit0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dilaveris</surname><given-names>PE</given-names></name><name><surname>Gialafos</surname><given-names>EJ</given-names></name></person-group><article-title>P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation</article-title><source>Ann Noninvas Electrocardiol</source><year>2001</year><volume>6</volume><fpage>159</fpage><lpage>65</lpage></element-citation></ref><ref id="cit0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>B</given-names></name><name><surname>Gonzales</surname><given-names>A</given-names></name><name><surname>Varo</surname><given-names>N</given-names></name><name><surname>Laviades</surname><given-names>C</given-names></name><name><surname>Querejeta</surname><given-names>R</given-names></name><name><surname>Diez</surname><given-names>J</given-names></name></person-group><article-title>Biochemical assessment of myocardial fibrosis in hypertensive heart disease</article-title><source>Hypertension</source><year>2001</year><volume>38</volume><fpage>1222</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11711527</pub-id></element-citation></ref><ref id="cit0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risteli</surname><given-names>J</given-names></name><name><surname>Elomaa</surname><given-names>I</given-names></name><name><surname>Nenni</surname><given-names>S</given-names></name><name><surname>Vovamo</surname><given-names>A</given-names></name><name><surname>Risteli</surname><given-names>L</given-names></name></person-group><article-title>Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type 1 collagen: a new serum marker of collagen degradation</article-title><source>Clin Chem</source><year>1993</year><volume>39</volume><fpage>635</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8472358</pub-id></element-citation></ref><ref id="cit0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewing</surname><given-names>DJ</given-names></name><name><surname>Clarke</surname><given-names>BF</given-names></name></person-group><article-title>Diagnosis and management of diabetic autonomic neuropathy</article-title><source>Br Med J</source><year>1982</year><volume>285</volume><fpage>916</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">6811067</pub-id></element-citation></ref><ref id="cit0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chudzik</surname><given-names>M</given-names></name><name><surname>Cygankiewicz</surname><given-names>I</given-names></name><name><surname>Klimczak</surname><given-names>A</given-names></name><name><surname>Lewek</surname><given-names>J</given-names></name><name><surname>Bartczak</surname><given-names>K</given-names></name><name><surname>Wranicz</surname><given-names>JK</given-names></name></person-group><article-title>Short-term ECG recordings for heart rate assessment in patients with chronic atrial fibrillation</article-title><source>Arch Med Sci</source><year>2014</year><volume>10</volume><fpage>676</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">25276150</pub-id></element-citation></ref><ref id="cit0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meikko</surname><given-names>J</given-names></name><name><surname>Niemi</surname><given-names>S</given-names></name><name><surname>Risteli</surname><given-names>J</given-names></name></person-group><article-title>Radioimmunoassay of the carboxyterminal propetide of human type I procollagen</article-title><source>Clin Chem</source><year>1990</year><volume>36</volume><fpage>1328</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">2372946</pub-id></element-citation></ref><ref id="cit0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermes</surname><given-names>E</given-names></name><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Bourassa</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction</article-title><source>Insights from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation</source><year>2003</year><volume>107</volume><fpage>2926</fpage><lpage>31</lpage></element-citation></ref><ref id="cit0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fogari</surname><given-names>R</given-names></name><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>I</given-names></name><etal/></person-group><article-title>Effect of valsartan and ramipril on atrial fibrillation recurrence and p-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation</article-title><source>Am J Hypertens</source><year>2008</year><volume>21</volume><fpage>1034</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18566593</pub-id></element-citation></ref><ref id="cit0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fogari</surname><given-names>R</given-names></name><name><surname>Mugellini</surname><given-names>A</given-names></name><name><surname>Zoppi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation</article-title><source>J Cardiovasc Pharmac Ther</source><year>2012</year><volume>17</volume><fpage>34</fpage><lpage>43</lpage></element-citation></ref><ref id="cit0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>H</given-names></name><name><surname>Kumagai</surname><given-names>K</given-names></name><name><surname>Urata</surname><given-names>H</given-names></name><name><surname>Gondo</surname><given-names>N</given-names></name><name><surname>Ideishi</surname><given-names>M</given-names></name><name><surname>Arakawa</surname><given-names>K</given-names></name></person-group><article-title>Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>2612</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10840013</pub-id></element-citation></ref><ref id="cit0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrlich</surname><given-names>R</given-names></name><name><surname>Hohmloser</surname><given-names>SH</given-names></name><name><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><fpage>512</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16311236</pub-id></element-citation></ref><ref id="cit0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozdemir</surname><given-names>O</given-names></name><name><surname>Sylu</surname><given-names>M</given-names></name><name><surname>Demir</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Does P-wave dispersion predict the atrial fibrillation occurrence after direct-current shock</article-title><source>Angiology</source><year>2006</year><volume>57</volume><fpage>93</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16444462</pub-id></element-citation></ref><ref id="cit0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goette</surname><given-names>A</given-names></name><name><surname>Hoffmanns</surname><given-names>P</given-names></name><name><surname>Enayati</surname><given-names>W</given-names></name><name><surname>Meltendorf</surname><given-names>U</given-names></name><name><surname>Geller</surname><given-names>JC</given-names></name><name><surname>Klein</surname><given-names>HU</given-names></name></person-group><article-title>Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation</article-title><source>Am J Cardiol</source><year>2001</year><volume>88</volume><fpage>906</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11676961</pub-id></element-citation></ref><ref id="cit0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazlo</surname><given-names>R</given-names></name><name><surname>Bentz</surname><given-names>K</given-names></name><name><surname>Schreieck</surname><given-names>J</given-names></name></person-group><article-title>Effects of aldosterone and mineralcorticoid receptor antagonism on cardiac ion channels in the view of upstream therapy of atrial fibrillation</article-title><source>Gen Physiol Biophys</source><year>2011</year><volume>30</volume><fpage>11</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21460407</pub-id></element-citation></ref><ref id="cit0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lendeckel</surname><given-names>U</given-names></name><name><surname>Dobrev</surname><given-names>D</given-names></name><name><surname>Goette</surname><given-names>A</given-names></name></person-group><article-title>Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation</article-title><source>Br J Pharmac</source><year>2010</year><volume>159</volume><fpage>1581</fpage><lpage>3</lpage></element-citation></ref><ref id="cit0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallergis</surname><given-names>EM</given-names></name><name><surname>Manios</surname><given-names>EG</given-names></name><name><surname>Kanoupakis</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>211</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18617070</pub-id></element-citation></ref><ref id="cit0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>B</given-names></name><name><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Atrial fibrosis</article-title><source>Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol</source><year>2008</year><volume>51</volume><fpage>802</fpage><lpage>9</lpage></element-citation></ref><ref id="cit0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boldt</surname><given-names>A</given-names></name><name><surname>Scholl</surname><given-names>A</given-names></name><name><surname>Garbade</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ace-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation</article-title><source>Basic Res Cardiol</source><year>2006</year><volume>101</volume><fpage>261</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16382287</pub-id></element-citation></ref><ref id="cit0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reil</surname><given-names>JC</given-names></name><name><surname>Hohl</surname><given-names>M</given-names></name><name><surname>Selejan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Aldosterone promotes atrial fibrillation</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><fpage>2098</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">21816854</pub-id></element-citation></ref><ref id="cit0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavall</surname><given-names>D</given-names></name><name><surname>Selzer</surname><given-names>C</given-names></name><name><surname>Schuster</surname><given-names>P</given-names></name><etal/></person-group><article-title>The mineralcorticoid receptor promotes fibrotic remodeling in atrial fibrillation</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>6656</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">24469458</pub-id></element-citation></ref><ref id="cit0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struthers</surname><given-names>AD</given-names></name></person-group><article-title>Aldosterone escape during ACE inhibition therapy in chronic heart failure</article-title><source>Eur Heart J</source><year>1995</year><volume>16</volume><issue>Suppl</issue><fpage>103</fpage><lpage>6</lpage></element-citation></ref><ref id="cit0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urata</surname><given-names>H</given-names></name><name><surname>Nishimura</surname><given-names>H</given-names></name><name><surname>Ganten</surname><given-names>D</given-names></name></person-group><article-title>Chymase dependent Ang II forming system in humans</article-title><source>Am J Hypertens</source><year>1996</year><volume>9</volume><fpage>277</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8695029</pub-id></element-citation></ref><ref id="cit0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wachtell</surname><given-names>K</given-names></name><name><surname>Letho</surname><given-names>M</given-names></name><name><surname>Gerdts</surname><given-names>E</given-names></name><etal/></person-group><article-title>Ang II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End-Point Reduction in Hypertension (LIFE) study</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>45</volume><fpage>712</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15734615</pub-id></element-citation></ref><ref id="cit0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Latini</surname><given-names>R</given-names></name><name><surname>Carson</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)</article-title><source>Am Heart J</source><year>2005</year><volume>149</volume><fpage>548</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">15864246</pub-id></element-citation></ref></ref-list></back></article>